| abstract |
Composition for the prophylaxis, treatment or reduction of exacerbations associated with a lung disease comprising an effective amount of a PDE4 inhibitor, an effective amount of an H1 receptor antagonist, and a pharmaceutically acceptable excipient. The PDE4 inhibitor can be cis- [cyano-4- (3-cyclopentyloxy-4-methoxyphenyl) cyclohexane--1-carboxylate], roflumilast or N- (3,5-dichloropyrid --- 4-yl) -2- [1- (4-Fluorobenzyl) -5- -hydroxyindole-3-yl] -2-oxoacetamide), and the H1 receptor antagonist is astemizole, levocabastine HCI, loratadine or its decarboethoxylated analog compound, terfenadine or fexofenadine hydrochloride. The composition may be in the form of an oral tablet, a dry powder for use in a dry powder inhaler, or an aqueous preparation for nasal administration. Use of an effective amount of a PDE4 inhibitor and an effective amount of an H1 receptor antagonist for the manufacture of said pharmaceutical composition. |